ArticleInternational journal of clinical and experimental pathology2017
Ursodeoxycholic acid induces autophagy via LC3B to suppress hepatocellular carcinoma in vivo and in vitro.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 6 citations in OpenAlex.
- Gut microbiota modulation of gastrointestinal cancers: from dysbiosis signatures to therapeutic interventions.Acta pharmacologica Sinica · 2026Review
- EGR1 Mediates Ursodeoxycholic Acid-Promoted Mitophagy to Prevent Postovulatory Aging of Porcine Oocytes.Aging cell · 2026Article
- Neuroprotective effects of ursodeoxycholic acid in Parkinson's disease and Alzheimer's disease.Neuroprotection (Chichester, England) · 2026Review
- Ursodeoxycholic acid inhibits pneumonia caused by PRCV through the activation of TLR4-IRF3 mediated type Ⅰ interferon pathway.Veterinary research · 2026Article
- Ursodeoxycholic acid inhibits the uptake of cystine through SLC7A11 and impairsJournal of pharmaceutical analysis · 2025Article
- Carcinogenic and anticancer activities of microbiota-derived secondary bile acids.Frontiers in oncology · 2025Review
- Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma.Cancer biology & medicine · 2023Review
- Targeting and regulation of autophagy in hepatocellular carcinoma: revisiting the molecular interactions and mechanisms for new therapy approaches.Cell communication and signaling : CCS · 2023Review
- Neuroprotective activity of ursodeoxycholic acid in CHMP2BNeurobiology of disease · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsHepatocellular carcinoma (HCC) is a common cancer worldwide. Researchers have found that UDCA can be used to inhibit the growth of tumors. Microtubule-associated protein light chain 3B (LC3B) is an important reglator of autophagosomes. No researches have been published on the relationship of UDCA and LC3B.
methodsA Cell Counting Kit-8 cell viability assay, cell migration assay, quantitative reverse transcription PCR (qRT-PCR) and western blot were conducted for the SMMC-7721 and HepG2 cell lines. Hematoxylin-eosin (HE) staining and immunohistochemistry (IHC) were used to analyze nude mice with 7721 xenograftes. The expression of LC3B was evaluated both in vivo and in vitro.
resultsOur studies demonstrated that UDCA reduced the viability of the primary HCC cell lines 7721 and HepG2 (Student's t-test,
conclusionOur data showed that UDCA promoted the expression of LC3B, with suppressed HCC in vivo and in vitro.
Indexed as
Identifiers
31966544PMC6966075W3011230370What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.